Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues - Observations in two patients with acromegaly and severe headache.

Djordje Marina, Pia Burman, Marianne Klose, Olivera Casar-Borota, Raúl M Luque, Justo P Castaño, Ulla Feldt-Rasmussen

Research output: Contribution to journalArticlepeer-review

Abstract

Somatotropinomas have unique "fingerprints" of somatostatin receptor (sst) expression, which are targets in treatment of acromegaly with somatostatin analogues (SSAs). However, a significant expression of sst is not always related to the biochemical response to SSAs. Headache is a common complaint in acromegaly and considered a clinical marker of disease activity. SSAs are reported to have an own analgesic effect, but the sst involved are unknown.
Original languageEnglish
Pages (from-to)262-267
JournalGrowth Hormone & Igf Research
Volume25
Issue number5
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Endocrinology and Diabetes

Fingerprint

Dive into the research topics of 'Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues - Observations in two patients with acromegaly and severe headache.'. Together they form a unique fingerprint.

Cite this